Skip to main navigation Skip to search Skip to main content

Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples

  • Ke Hung Tsui
  • , Horng Heng Juang
  • , Tsong Hai Lee
  • , Phei Lang Chang
  • , Chien Lun Chen
  • , Benjamin Yat Ming Yung

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To investigate the possible correlation of nucleophosmin/B23 expression with bladder carcinoma recurrence. Methods: Surgically-resected bladder tumors staged pTa to pT4 were examined for nucleophosmin/B23 expression by immuno-histochemistry. The study group consisted of 132 consecutive patients surgically treated at Chang Gung Memorial Hospital between December 1998 and November 1999. The mean follow up was 72 months (range: 48-84 months). Results: Nuclear nucleophosmin/B23 staining was detected in 96% of advanced stage and poorly-differentiated tumors. Higher nucleophosmin/B23 levels were linked to more advanced tumor stages, grades, poor prognosis, and likelihood of recurrence (P<0.05). The Cox multivariate analysis indicated the nucleophosmin/B23 expression as an independent indicator for tumor recurrence (P=0.009). Conclusion: The results suggest that nucleophosmin/B23 is a favorable prognostic indicator for bladder cancer. Nucleophosmin/B23 could be a useful molecular tumor marker for predicting bladder cancer recurrence.

Original languageEnglish
Pages (from-to)364-370
Number of pages7
JournalActa Pharmacologica Sinica
Volume29
Issue number3
DOIs
Publication statusPublished - Mar 2008
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Bladder carcinoma recurrence
  • Immunohistochemistry
  • Nucleophosmin/B23

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples'. Together they form a unique fingerprint.

Cite this